Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02716688 | S-1 and Radiotherapy for Elderly Esophageal Cancer Patients | withdrawn | Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT02535988 | Abscopal Effect for Metastatic Colorectal Cancer | withdrawn | Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 0 | Sep 21, 2023 | clinicaltrials |
| SOX-based CRT for Esophageal Cancer. |
| withdrawn |
| Phase 1 / Phase 2 |
| 0 |
| Zhejiang Provincial People's HospitalOTHER |
| 1 |
| Sep 21, 2023 |
| clinicaltrials |
| NCT05412706 | Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy(Bohème) | withdrawn | Phase 2 | 0 | Ospedale Policlinico San MartinoOTHER | 0 | Sep 8, 2023 | clinicaltrials |
| NCT05043987 | Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers | withdrawn | Phase 1 | 0 | Conjupro Biotherapeutics, Inc.INDUSTRY | 0 | Sep 7, 2023 | clinicaltrials |
| NCT05379907 | Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer | withdrawn | — | 0 | Inova Health Care ServicesOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05510427 | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 15, 2023 | clinicaltrials |
| NCT04591028 | A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in Gastric Cancer Patients | withdrawn | Phase 4 | 0 | Mayo ClinicOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05951842 | Anesthesia, TIVA, Balanced Anesthesia, NK Cell | withdrawn | N/A | 0 | Gangnam Severance HospitalOTHER | 0 | Jul 19, 2023 | clinicaltrials |
| NCT05109052 | Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of RochesterOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT03722498 | Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05216120 | Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas | withdrawn | Phase 2 | 0 | HonorHealth Research InstituteOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT02515513 | The Role of Muscle Cachexia in Pancreatic Cancer | withdrawn | N/A | 0 | University of FloridaOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05431582 | Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT05411679 | EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Ellipses PharmaINDUSTRY | 3 | Jun 12, 2023 | clinicaltrials |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers(REFIT-MSS) | withdrawn | Phase 2 | 0 | Translational Research in OncologyOTHER | 0 | Jun 7, 2023 | clinicaltrials |
| NCT05886257 | Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T | withdrawn | Phase 2 | 0 | Shi MingOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT02344810 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT04535492 | Technology-Based Cancer Screening Intervention | withdrawn | N/A | 0 | Medical University of South CarolinaOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05251038 | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Devalingam MahalingamOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT02174575 | Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | withdrawn | Phase 4 | 0 | Tokyo Medical and Dental UniversityOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT03999658 | A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies | withdrawn | Phase 2 | 0 | Sorrento Therapeutics, Inc.INDUSTRY | 0 | May 1, 2023 | clinicaltrials |
| NCT02682485 | Serial Endoscopic Surveillance & Direct Topical Antibiotics to Define the Role of Microbes in Anastomotic Healing(SES-DTA) | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 0 | Apr 26, 2023 | clinicaltrials |
| NCT05246943 | The Correlation of a D-dimer Testing Protocol With Venous Thromboembolism in Surgical Colorectal Patients | withdrawn | — | 0 | The University of Texas Medical Branch, GalvestonOTHER | 0 | Apr 25, 2023 | clinicaltrials |
| NCT04852367 | PanDox: Targeted Doxorubicin in Pancreatic Tumours(PanDox) | withdrawn | Phase 1 | 0 | University of OxfordOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05183295 | Medical Food for the Dietary Management of Metastatic Colorectal Cancer | withdrawn | N/A | 0 | Faeth TherapeuticsINDUSTRY | 0 | Apr 3, 2023 | clinicaltrials |
| NCT00430313 | Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin | withdrawn | N/A | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 29, 2023 | clinicaltrials |
| NCT05157451 | Y-90 Versus SBRT for Inoperable HCC | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Mar 23, 2023 | clinicaltrials |
| NCT03742596 | Effect of Probiotics Supplementation on the Side Effects of Radiation Therapy Among Colorectal Cancer Patients | withdrawn | Phase 2 / Phase 3 | 0 | King Hussein Cancer CenterOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT01792882 | Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples(GBCPRT0008) | withdrawn | — | 0 | Global BioClinicalINDUSTRY | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05606081 | Predicting Risk for Post-polypectomy Colorectal Cancer(PREDICT) | withdrawn | N/A | 0 | Kaiser PermanenteOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT02899325 | FDGal PET/CT to Detect Hepatocellular Carcinoma | withdrawn | — | 0 | British Columbia Cancer AgencyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04021082 | CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) | withdrawn | Phase 2 / Phase 3 | 0 | Portola PharmaceuticalsINDUSTRY | 0 | Feb 21, 2023 | clinicaltrials |
| NCT05730673 | Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer | withdrawn | Phase 2 | 0 | CytoDyn, Inc.INDUSTRY | 0 | Feb 17, 2023 | clinicaltrials |
| NCT04965714 | Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05592197 | Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT | withdrawn | N/A | 0 | Sun Yat-sen UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors(MATILDA) | withdrawn | Phase 2 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT05628545 | Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells | withdrawn | Phase 1 / Phase 2 | 0 | Guangdong GD Kongming Biotech LLCINDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT04868747 | The Effect of Perioperative Lidocaine Infusion on Neutrophil Extracellular Trapping | withdrawn | N/A | 0 | The Catholic University of KoreaOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT04178642 | The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol(LIDA-ADJ) | withdrawn | Phase 2 | 0 | University Hospital, MontpellierOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05327738 | Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Dec 14, 2022 | clinicaltrials |
| NCT05245760 | ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer(CRATER) | withdrawn | Phase 2 | 0 | Zhonglin HaoOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT04639843 | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2022 | clinicaltrials |
| NCT05178576 | A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy | withdrawn | Phase 2 | 0 | NSABP Foundation IncNETWORK | 1 | Nov 4, 2022 | clinicaltrials |
| NCT05431244 | Pilot Study of Antiviral Treatment in Combination With Low-dose Gemcitabine in EBV-associated Gastric Cancer (EBVaGC) | withdrawn | N/A | 0 | Samsung Medical CenterOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT05433402 | Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Sadat City UniversityOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT00954876 | Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer | withdrawn | Phase 2 | 0 | Translational Genomics Research InstituteOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT04420130 | A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009） | withdrawn | N/A | 0 | Yanqiao ZhangOTHER | 0 | Oct 4, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Sep 22, 2023source: clinicaltrials